Preterm birth rates continue to rise globally, prompting healthcare providers to seek ways to improve care for this vulnerable patient group. The rate varies between 5-11% in the western countries and the medical care of these preterm born infants presents unique challenges and requires specialized methods of diagnosis and treatment. As their lungs are not fully developed, pulmonary disorders, such as respiratory distress syndrome, are common in these neonates and require prompt detection, diagnosis, and treatment to improve patient outcomes. This is where Neola® comes in as a potential game-changer in the Neonatal Intensive Care Unit (NICU), offering a non-invasive, and continuous monitoring of the lungs of neonates. Based on cutting-edge optical technology, Gas-in-scattering-media absorption spectroscopy (GASMAS), variations in the lung volume and free oxygen gas concentration in the patient’s lungs are detected instantaneously. This provides effective lung monitoring for early detection of, possibly life-threatening or irreversible, pulmonary disorders, allowing treatment to start promptly. By bringing this medical device to the market, Neola Medical aims to save more lives, reduce the need for extensive hospitalization, and improve the quality of life for millions of preterm born babies.
Read more here: White Paper